Skip to main content

RAS Collaborations

The RAS Initiative has engaged in numerous formal collaborations with both organizations and individual scientists.  These arrangements bring outside expertise to the Initiative's project areas to apply the best ideas and newest technologies to attack the worst cancer gene.

Community Collaborations

The combined expertise of RAS Initiative researchers and the following outside organizations have expanded research capabilities and resulted in synergistic efforts to drive discoveries.

Pancreatic Cancer Action Network

Of all the cancers, pancreatic cancer is the one most often driven by mutations in RAS genes. The Pancreatic Cancer Action Network (PanCan) advocates for patients and raises funds for research. PanCan has coordinated with the RAS Initiative to fund postdoctoral awards and fellowships that complement the Initiative's work at the Frederick National Laboratory.

DARPA Big Mechanism Program

The Defense Advanced Research Projects Agency (DARPA) has established the Big Mechanism program to use machine learning to read abstracts and papers from the scientific literature to develop causal, explanatory relationships. The RAS Initiative is cooperating with the Big Mechanism Program to try to understand and reveal new ways to look at the RAS signaling network.

Department of Energy Pilot Program

The Department of Energy (DOE) maintains vast computational power as part of its own national missions. The DOE’s Molecular Level Pilot Program and the RAS Initiative are cooperating to apply the DOE’s unique capabilities to better model and understand how individual RAS molecules behave at the membrane in living cells.

Technical Collaborations

Decades of effort by thousands of researchers around the world have resulted in numerous specialized tools and areas of knowledge that can be applied to better understand how cancers work. Scientists in the RAS Initiative have established cooperative relationships with outside experts to access the capabilities that are most important to attack mutant RAS.

  • Mariano Barbacid, Spanish National Cancer Research Center
  • Cyril Benes, Massachusetts General Hospital
  • Marco Biancucci, Northwestern University - Chicago
  • Larry Botticelli, Pharma Arava, LLC
  • Arul Chinnaiyan, University of Michigan
  • Geoffrey Clark, University of Louisville
  • Channing Der, University of North Carolina
  • Martin Drysdale, Beatson Institute
  • Walter Englaro, Sanofi-Aventis
  • Sandra Gabelli, Johns Hopkins
  • Angel Garcia, Los Alamos National Lab
  • William Garland, Tosk, Inc.
  • Rodolfo Ghirlando, NIDDK
  • Michael Gross, Washington University
  • Jay Groves, University of California - Berkeley
  • Frank Heinrich, National Institute for Standards and Technology
  • Paul Henderson, University of California - Davis
  • John Hunter, University of Texas - Southwestern
  • Esmaiel Jabbari, University of South Carolina
  • Hans Robert Kalbitzer, University of Regensburg - Germany
  • Perry Kennedy, H. Lee Moffitt Cancer Center & Research Institute
  • Rich Klinghoffer, Presage Biosciences
  • Krishna Kota and Rajini Mudhasani, United States Army Medical Research Institute for Infectious Diseases
  • Nir London, Weizmann Institute
  • Ji Luo, National Cancer Institute
  • Carla Mattos, Northeastern University
  • Lynn McGregor, University of California - San Francisco
  • Campbell McInnes, PPI Pharmaceuticals
  • Debbie Morrison, National Cancer Institute
  • Bjoern Papke, The University of North Carolina at Chapel Hill
  • Arvind Ramanthan, Oak Ridge National Lab
  • Adam Renslo, University of California - San Francisco
  • Robert Rottapel, University of Toronto
  • Udo Rudloff, National Cancer Institute
  • Saori Fujita Sato, Daiichi-Sankyo
  • Karla Satchell, Northwestern University
  • Brian Shoichet, University of California - San Francisco
  • Kevan Shokat, University of California - San Francisco
  • Anton Simeonov, National Center for Advancing Translational Sciences
  • Kamini Singh, Memorial Sloan Kettering Cancer Center
  • Steve Sligar, University of Illinois
  • Chris Stanley, Oak Ridge National Laboratory
  • Fred Streitz, Lawrence Livermore National Lab
  • Rick Stevens, Argonne National Lab
  • Sriram Subramaniam, National Cancer Institute
  • Marco Tonelli, Nuclear Magnetic Resonance Facility at Madison, Wisconsin
  • David Webber, University of Maryland
  • Jim Wells, University of California - San Francisco
  • Ken Westover, University of Texas - Southwestern
  • Fred Wittinghofer, Max Planck Institute
  • Kris Wood, Duke University
  • Tina Yuan, Broad Institute
  • Posted: